Insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Arcturus Therapeutics Holdings Inc. (ARCT) since 2019 are shown in Table 1 and Table 2. Table 1 shows the monthly insider trading data of Arcturus Therapeutics Holdings Inc.. Table 2 shows the detailed insider transactions. This company's CIK number is 1768224.
Total stock buying since 2019: $787,847.
Total stock sales since 2019: $137,439,868.
Total stock option exercises since 2019: $9,730,760.
| Insider Buying | Insider Sales | Option Exercises | ||||
|---|---|---|---|---|---|---|
| Year | Shares | Value | Shares | Value | Shares | Value |
| 2025 | 1,238 | $20,498 | 0 | $0 | 0 | $0 |
| 2024 | 0 | $0 | 88,114 | $2,766,166 | 18,786 | $0 |
| 2023 | 0 | $0 | 108,936 | $3,237,313 | 13,936 | $130,760 |
| 2022 | 7,222 | $122,546 | 8,100 | $324,000 | 0 | $0 |
| 2021 | 0 | $0 | 890,000 | $48,067,156 | 0 | $0 |
| 2020 | 6,450 | $195,388 | 840,000 | $83,045,233 | 600,000 | $9,600,000 |
| 2019 | 42,562 | $449,415 | 0 | $0 | 0 | $0 |
| Trading Period | Insider Buying | Insider Sales | Option Exercises | |||
|---|---|---|---|---|---|---|
| year-month | Shares | Value | Shares | Value | Shares | Value |
| 2025-08 | 1,238 | $20,498 | 0 | $0 | 0 | $0 |
| 2024-10 | 0 | $0 | 12,000 | $249,120 | 0 | $0 |
| 2024-06 | 0 | $0 | 50,114 | $1,606,630 | 18,786 | $0 |
| 2024-03 | 0 | $0 | 26,000 | $910,416 | 0 | $0 |
| 2023-11 | 0 | $0 | 5,000 | $93,600 | 0 | $0 |
| 2023-10 | 0 | $0 | 5,000 | $128,059 | 0 | $0 |
| 2023-09 | 0 | $0 | 5,000 | $157,265 | 0 | $0 |
| 2023-08 | 0 | $0 | 5,000 | $174,549 | 0 | $0 |
| 2023-07 | 0 | $0 | 36,968 | $1,262,880 | 6,968 | $65,380 |
| 2023-06 | 0 | $0 | 5,000 | $135,800 | 0 | $0 |
| 2023-05 | 0 | $0 | 30,000 | $881,552 | 0 | $0 |
| 2023-04 | 0 | $0 | 11,968 | $323,258 | 6,968 | $65,380 |
| 2023-03 | 0 | $0 | 5,000 | $80,350 | 0 | $0 |
| 2022-12 | 2,222 | $39,996 | 0 | $0 | 0 | $0 |
| 2022-11 | 5,000 | $82,550 | 0 | $0 | 0 | $0 |
| 2022-01 | 0 | $0 | 8,100 | $324,000 | 0 | $0 |
| 2021-12 | 0 | $0 | 10,000 | $400,007 | 0 | $0 |
| 2021-11 | 0 | $0 | 10,000 | $444,099 | 0 | $0 |
| 2021-10 | 0 | $0 | 10,000 | $443,600 | 0 | $0 |
| 2021-09 | 0 | $0 | 10,000 | $558,600 | 0 | $0 |
| 2021-08 | 0 | $0 | 810,000 | $44,031,950 | 0 | $0 |
| 2021-04 | 0 | $0 | 10,000 | $429,500 | 0 | $0 |
| 2021-03 | 0 | $0 | 10,000 | $542,300 | 0 | $0 |
| 2021-02 | 0 | $0 | 10,000 | $753,100 | 0 | $0 |
| Trade Date | Insider Name | Trade Type | Shares | Price ($) | Value ($) |
|---|---|---|---|---|---|
| 2025-08-15 | Sassine Andy (Chief Financial Officer) | Buy | 1,238 | 16.56 | 20,498 |
| 2024-10-15 | Chivukula Pad (Chief Scientific Officer & COO) | Sale | 12,000 | 20.76 | 249,120 |
| 2024-06-14 | Marantz Jing L. | Option Ex | 3,131 | .00 | 0 |
| 2024-06-14 | Markels John | Option Ex | 3,131 | .00 | 0 |
| 2024-06-14 | Marquet Magda | Option Ex | 3,131 | .00 | 0 |
| 2024-06-14 | Holmes Edward W | Option Ex | 3,131 | .00 | 0 |
| 2024-06-14 | Barlow James F | Option Ex | 3,131 | .00 | 0 |
| 2024-06-14 | Farrell Peter C | Option Ex | 3,131 | .00 | 0 |
| 2024-06-12 | Sassine Andy (Chief Financial Officer) | Sale | 50,000 | 32.03 | 1,601,500 |
| 2024-06-05 | Chivukula Pad (Chief Scientific Officer & COO) | Sale | 114 | 45.00 | 5,130 |
| 2024-03-25 | Chivukula Pad (Chief Scientific Officer & COO) | Sale | 17,435 | 35.02 | 610,573 |
| 2024-03-19 | Chivukula Pad (Chief Scientific Officer & COO) | Sale | 8,565 | 35.01 | 299,843 |
| 2023-11-01 | Chivukula Pad (Chief Scientific Officer & COO) | Sale | 5,000 | 18.72 | 93,600 |
| 2023-10-02 | Chivukula Pad (Chief Scientific Officer & COO) | Sale | 5,000 | 25.61 | 128,059 |
| 2023-09-01 | Chivukula Pad (Chief Scientific Officer & COO) | Sale | 5,000 | 31.45 | 157,265 |
| 2023-08-01 | Chivukula Pad (Chief Scientific Officer & COO) | Sale | 5,000 | 34.91 | 174,549 |
| 2023-07-14 | Kummerfeld Keith C (See Remarks) | Sale | 6,968 | 35.00 | 243,880 |
| 2023-07-14 | Kummerfeld Keith C (See Remarks) | Option Ex | 6,968 | 9.38 | 65,380 |
| 2023-07-14 | Chivukula Pad (Chief Scientific Officer & COO) | Sale | 25,000 | 35.01 | 875,250 |
| 2023-07-03 | Chivukula Pad (Chief Scientific Officer & COO) | Sale | 5,000 | 28.75 | 143,750 |
| 2023-06-01 | Chivukula Pad (Chief Scientific Officer & COO) | Sale | 5,000 | 27.16 | 135,800 |
| 2023-05-11 | Chivukula Pad (Chief Scientific Officer & COO) | Sale | 7,925 | 30.24 | 239,652 |
| 2023-05-10 | Chivukula Pad (Chief Scientific Officer & COO) | Sale | 17,075 | 30.00 | 512,250 |
| 2023-05-01 | Chivukula Pad (Chief Scientific Officer & COO) | Sale | 5,000 | 25.93 | 129,650 |
| 2023-04-18 | Kummerfeld Keith C (See Remarks) | Sale | 6,968 | 28.18 | 196,358 |
| 2023-04-18 | Kummerfeld Keith C (See Remarks) | Option Ex | 6,968 | 9.38 | 65,380 |
| 2023-04-03 | Chivukula Pad (Chief Scientific Officer & COO) | Sale | 5,000 | 25.38 | 126,900 |
| 2023-03-06 | Chivukula Pad (Chief Scientific Officer & COO) | Sale | 5,000 | 16.07 | 80,350 |
| 2022-12-15 | Marquet Magda | Buy | 2,222 | 18.00 | 39,996 |
| 2022-11-23 | Payne Joseph E (President and CEO) | Buy | 5,000 | 16.51 | 82,550 |
| 2022-01-04 | Chivukula Pad (Chief Scientific Officer & COO) | Sale | 8,100 | 40.00 | 324,000 |
| 2021-12-16 | Chivukula Pad (Chief Scientific Officer & COO) | Sale | 3,633 | 40.00 | 145,327 |
| 2021-12-08 | Chivukula Pad (Chief Scientific Officer & COO) | Sale | 6,367 | 40.00 | 254,680 |
| 2021-11-01 | Chivukula Pad (Chief Scientific Officer & COO) | Sale | 10,000 | 44.41 | 444,099 |
| 2021-10-01 | Chivukula Pad (Chief Scientific Officer & COO) | Sale | 10,000 | 44.36 | 443,600 |
| 2021-09-01 | Chivukula Pad (Chief Scientific Officer & COO) | Sale | 10,000 | 55.86 | 558,600 |
| 2021-08-11 | Ultragenyx Pharmaceutical Inc. (Director) | Sale | 75,000 | 45.83 | 3,437,250 |
| 2021-08-10 | Ultragenyx Pharmaceutical Inc. (Director) | Sale | 725,000 | 55.44 | 40,194,000 |
| 2021-08-03 | Chivukula Pad (Chief Scientific Officer & COO) | Sale | 10,000 | 40.07 | 400,700 |
| 2021-04-01 | Chivukula Pad (Chief Scientific Officer & COO) | Sale | 10,000 | 42.95 | 429,500 |
| 2021-03-01 | Chivukula Pad (Chief Scientific Officer & COO) | Sale | 10,000 | 54.23 | 542,300 |
| 2021-02-01 | Chivukula Pad (Chief Scientific Officer & COO) | Sale | 10,000 | 75.31 | 753,100 |
| 2021-01-04 | Chivukula Pad (Chief Scientific Officer & COO) | Sale | 10,000 | 46.40 | 464,000 |
| 2020-12-09 | Ultragenyx Pharmaceutical Inc. (Director) | Sale | 357,745 | 94.97 | 33,975,042 |
| 2020-12-08 | Ultragenyx Pharmaceutical Inc. (Director) | Sale | 442,255 | 105.54 | 46,675,592 |
| 2020-12-01 | Chivukula Pad (Chief Scientific Officer & COO) | Sale | 10,000 | 96.19 | 961,900 |
| 2020-11-02 | Chivukula Pad (Chief Scientific Officer & COO) | Sale | 10,000 | 55.28 | 552,800 |
| 2020-10-01 | Chivukula Pad (Chief Scientific Officer & COO) | Sale | 10,000 | 42.83 | 428,300 |
| 2020-09-03 | Chivukula Pad (Chief Scientific Officer & COO) | Sale | 10,000 | 45.16 | 451,599 |
| 2020-06-12 | Kummerfeld Keith C (See Remarks) | Buy | 450 | 33.33 | 14,998 |
| 2020-06-10 | Payne Joseph E (President and CEO) | Buy | 1,000 | 31.69 | 31,690 |
| 2020-06-10 | Sassine Andy (Chief Financial Officer) | Buy | 5,000 | 29.74 | 148,700 |
| 2020-05-20 | Ultragenyx Pharmaceutical Inc. (Director) | Option Ex | 600,000 | 16.00 | 9,600,000 |
| 2019-12-05 | Sassine Andy (Chief Financial Officer) | Buy | 5,649 | 9.73 | 54,964 |
| 2019-12-03 | Sassine Andy (Chief Financial Officer) | Buy | 10,000 | 10.00 | 100,000 |
| 2019-09-13 | Marquet Magda (Director) | Buy | 2,300 | 10.58 | 24,334 |
| 2019-09-12 | Kummerfeld Keith C (See Remarks) | Buy | 500 | 10.69 | 5,346 |
| 2019-08-29 | Payne Joseph E (President and CEO) | Buy | 5,000 | 11.22 | 56,100 |
| 2019-08-23 | Sassine Andy (Chief Financial Officer) | Buy | 10,000 | 10.90 | 109,000 |
| 2019-08-20 | Farrell Peter C (Director) | Buy | 4,432 | 10.85 | 48,087 |
| 2019-08-19 | Farrell Peter C (Director) | Buy | 4,681 | 11.02 | 51,584 |
Insider trading activities including stock purchases, stock sales, and option exercises of ARCT listed in the above tables cannot be completely guaranteed as to their accuracy. For more insider trading information of Arcturus Therapeutics Holdings Inc. (symbol ARCT, CIK number 1768224) see the Securities and Exchange Commission (SEC) website.